Pfizer, Astellas say Xtandi drug combo reduces risk of metastasis, death in prostate cancer by 58%
Pfizer and Astellas touted more detailed data over the weekend on their drug Xtandi in a type of prostate cancer, which the companies say show the potential for Xtandi to be added to the standard of care if a label expansion is approved.
In the Phase III EMBARK trial, the companies tested out Xtandi plus leuprolide and Xtandi as a monotherapy against placebo plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence (BCR).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.